{"protocolSection":{"identificationModule":{"nctId":"NCT03519971","orgStudyIdInfo":{"id":"D933KC00001"},"secondaryIdInfos":[{"id":"2017-004397-34","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","officialTitle":"A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-03-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-09-07","type":"ACTUAL"},"completionDateStruct":{"date":"2025-12-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-03-23","studyFirstSubmitQcDate":"2018-05-04","studyFirstPostDateStruct":{"date":"2018-05-09","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-09-06","resultsFirstSubmitQcDate":"2024-12-16","resultsFirstPostDateStruct":{"date":"2025-01-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-27","lastUpdatePostDateStruct":{"date":"2025-10-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care \\[SoC\\] CRT) in patients with locally advanced, unresectable NSCLC (Stage III)."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Locally Advanced, Unresectable NSCLC, Carcinoma, NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","CARE_PROVIDER"]}},"enrollmentInfo":{"count":328,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1: Durvalumab + platinum-based chemotherapy and radiation","type":"EXPERIMENTAL","description":"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.\n\nAll patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:\n\n* cisplatin/etoposide\n* carboplatin/paclitaxel\n* pemetrexed/cisplatin\n* pemetrexed/carboplatin\n\nAt the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment.","interventionNames":["Drug: Durvalumab","Drug: Cisplatin/ Etoposide","Drug: Carboplatin/ Paclitaxel","Drug: Pemetrexed/ Cisplatin","Drug: Pemetrexed/ Carboplatin","Radiation: Radiation"]},{"label":"Arm 2: Placebo + platinum-based chemotherapy and radiation","type":"PLACEBO_COMPARATOR","description":"Placebo in concurrence with platinum-based chemo-radiation therapy.\n\nAll patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:\n\n* cisplatin/etoposide\n* carboplatin/paclitaxel\n* pemetrexed/cisplatin\n* pemetrexed/carboplatin\n\nAt the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment.","interventionNames":["Other: Placebo","Drug: Cisplatin/ Etoposide","Drug: Carboplatin/ Paclitaxel","Drug: Pemetrexed/ Cisplatin","Drug: Pemetrexed/ Carboplatin","Radiation: Radiation"]}],"interventions":[{"type":"DRUG","name":"Durvalumab","description":"Durvalumab IV (intravenous infusion)","armGroupLabels":["Arm 1: Durvalumab + platinum-based chemotherapy and radiation"],"otherNames":["MEDI4736"]},{"type":"OTHER","name":"Placebo","description":"Placebo IV (intravenous infusion)","armGroupLabels":["Arm 2: Placebo + platinum-based chemotherapy and radiation"]},{"type":"DRUG","name":"Cisplatin/ Etoposide","description":"Cisplatin/ Etoposide, as per standard of care","armGroupLabels":["Arm 1: Durvalumab + platinum-based chemotherapy and radiation","Arm 2: Placebo + platinum-based chemotherapy and radiation"]},{"type":"DRUG","name":"Carboplatin/ Paclitaxel","description":"Carboplatin /Paclitaxel, as per standard of care","armGroupLabels":["Arm 1: Durvalumab + platinum-based chemotherapy and radiation","Arm 2: Placebo + platinum-based chemotherapy and radiation"]},{"type":"DRUG","name":"Pemetrexed/ Cisplatin","description":"Pemetrexed / Cisplatin, as per standard of care","armGroupLabels":["Arm 1: Durvalumab + platinum-based chemotherapy and radiation","Arm 2: Placebo + platinum-based chemotherapy and radiation"]},{"type":"DRUG","name":"Pemetrexed/ Carboplatin","description":"Pemetrexed / Carboplatin , as per standard of care","armGroupLabels":["Arm 1: Durvalumab + platinum-based chemotherapy and radiation","Arm 2: Placebo + platinum-based chemotherapy and radiation"]},{"type":"RADIATION","name":"Radiation","description":"5 fractions/ week for \\~6 weeks (±3 days) (Total 60 Gy)","armGroupLabels":["Arm 1: Durvalumab + platinum-based chemotherapy and radiation","Arm 2: Placebo + platinum-based chemotherapy and radiation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions. Median PFS was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days)."}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"The ORR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of complete response (CR) or partial response (PR) based on all participants in the FAS. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions.","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days)."},{"measure":"Overall Survival (OS)","description":"The OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. Median OS was calculated using the Kaplan-Meier technique.","timeFrame":"From screening until confirmed PD, assessed up to the DCO date (a maximum of approximately 1988 days)."},{"measure":"Percentage of Participants Alive at 24 Months From Randomization (OS24)","description":"The OS24 was defined as the Kaplan-Meier estimate of OS at 24 months. Median OS24 was calculated using the Kaplan-Meier technique.","timeFrame":"Month 24"},{"measure":"Complete Response Rate (CRR)","description":"The CRR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of CR. The CR was defined as disappearance of all target lesions since baseline.","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days)."},{"measure":"Duration of Response (DoR)","description":"The DoR per RECIST 1.1 using BICR was defined as the time from the date of first documented response (which was subsequently confirmed) until the first date of documented progression or death in the absence of PD. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions. The DoR was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days)."},{"measure":"Disease Control Rate (DCR)","description":"The DCR at 24 weeks per RECIST 1.1 using BICR was defined as the percentage of participants who had a best objective response of CR or PR in the first 25 weeks (to allow for late assessment within the assessment window) or who had stable disease for \\>= 23 weeks after randomization (to allow for an early assessment within the ± 1 week assessment window).","timeFrame":"Week 24"},{"measure":"Time to Death or Distant Metastasis (TTDM)","description":"The TTDM per RECIST 1.1 using BICR was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that was outside the radiation field according to RECIST 1.1 or proven by biopsy.","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days)."},{"measure":"Time From Randomization to Second Progression (PFS2)","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression event (subsequent to that used for the primary variable PFS per Investigator assessment) or death. The date of the second progression was recorded by the Investigator and defined according to local standard clinical practice and could have involved any of objective radiological, symptomatic progression, or death. Median PFS2 was calculated using the Kaplan-Meier technique.","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days)."},{"measure":"Serum Concentration of Durvalumab","description":"Blood samples were collected to determine the concentration of durvalumab.","timeFrame":"End of infusion on Week 0, pre-infusion on Weeks 4 and 12, and Month 3 follow-up"},{"measure":"Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab","description":"Blood samples were collected to determine the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence was defined as the number of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as either treatment-induced (post-baseline ADA positive only) or treatment-boosted ADA (baseline positive ADA titer that was boosted to \\>= 4-fold during the study period). Treatment-induced ADA was defined as ADA positive only post-baseline and not detected at baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive assessments with at least 16 weeks between the first and last positive assessment, or ADA positive at the last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment without fulfilling the conditions for persistently positive.","timeFrame":"Pre-dose on Day 1 of Cycles 1, 2 and 4"},{"measure":"Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Average Over 12 Months","description":"Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a total score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status scale with higher scores on the global health status/quality of life (QoL) and functioning scales representing better health status/function, but higher scores on symptom scales/items representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as a change from baseline of \\>=10.","timeFrame":"At screening, 2, 4, 6, 8, 12, 16, and 20 weeks after randomization, then every 8 weeks ±1 week up to 52 weeks, and then every 12 weeks ±1 week thereafter until PFS2. Assessed up to 12 months."},{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE is the development of any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of study treatment were those with action taken was 'Drug Permanently Discontinued' for any study treatment.","timeFrame":"From time of signature of informed consent up to 90 days after last dose of study treatment or up to the date of initiation of the first subsequent therapy, whichever occurs first, approximately 1988 days."}]},"eligibilityModule":{"eligibilityCriteria":"Principal inclusion criteria :\n\n* Subjects with histologically- or cytologically-documented NSCLC\n* Locally advanced, unresectable (Stage III) NSCLC\n* World Health Organisation (WHO) performance status 0-1\n* At least one measurable lesion, not previously irradiated\n* Must have a life expectancy of at least 12 weeks at randomization\n\nPrincipal exclusion criteria :\n\n* Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs.\n* Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines.\n* History of allogeneic organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders\n* Uncontrolled intercurrent illness\n* History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency\n* Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus\n* Mixed small cell and NSCLC histology\n* Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling\n* Known allergy or hypersensitivity to any of the IPs or any of the IP excipients.\n* Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jeffrey Bradley, MD","affiliation":"AstraZeneca","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Barretos","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Research Site","city":"Curitiba","zip":"81520-060","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"Research Site","city":"Florianópolis","zip":"88034-000","country":"Brazil","geoPoint":{"lat":-27.59667,"lon":-48.54917}},{"facility":"Research Site","city":"Fortaleza","zip":"60336-045","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Research Site","city":"Porto Alegre","zip":"90035-003","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"Porto Alegre","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"Porto Alegre","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"Ribeirão Preto","zip":"14021-636","country":"Brazil","geoPoint":{"lat":-21.1775,"lon":-47.81028}},{"facility":"Research Site","city":"Ribeirão Preto","zip":"14048900","country":"Brazil","geoPoint":{"lat":-21.1775,"lon":-47.81028}},{"facility":"Research Site","city":"São José do Rio Preto","zip":"15090-000","country":"Brazil","geoPoint":{"lat":-20.81972,"lon":-49.37944}},{"facility":"Research Site","city":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Research Site","city":"Brno","zip":"656 53","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Research Site","city":"Ostrava","zip":"703 00","country":"Czechia","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Research Site","city":"Prague","zip":"128 08","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Győr","zip":"9024","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Research Site","city":"Gyula","zip":"5700","country":"Hungary","geoPoint":{"lat":46.65,"lon":21.28333}},{"facility":"Research Site","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Research Site","city":"Bangalore","zip":"560068","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Research Site","city":"Chennai","zip":"600035","country":"India","geoPoint":{"lat":13.08784,"lon":80.27847}},{"facility":"Research Site","city":"Gūrgaon","zip":"122001","country":"India","geoPoint":{"lat":28.43549,"lon":79.13486}},{"facility":"Research Site","city":"Karamsad","zip":"388325","country":"India","geoPoint":{"lat":22.54243,"lon":72.90392}},{"facility":"Research Site","city":"Mumbai","zip":"400053","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Research Site","city":"Nashik","zip":"422005","country":"India","geoPoint":{"lat":19.99727,"lon":73.79096}},{"facility":"Research Site","city":"New Delhi","zip":"110063","country":"India","geoPoint":{"lat":28.62137,"lon":77.2148}},{"facility":"Research Site","city":"Vadodara","zip":"390007","country":"India","geoPoint":{"lat":22.29941,"lon":73.20812}},{"facility":"Research Site","city":"Bunkyō City","zip":"113-8603","country":"Japan","geoPoint":{"lat":35.5331,"lon":139.4217}},{"facility":"Research Site","city":"Fukuoka","zip":"812-8582","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Research Site","city":"Kōtoku","zip":"135-8550","country":"Japan","geoPoint":{"lat":42.50417,"lon":143.14297}},{"facility":"Research Site","city":"Kyoto","zip":"606-8507","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Research Site","city":"Nagoya","zip":"464-8681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Research Site","city":"Sayama","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"facility":"Research Site","city":"Sendai","zip":"980-0873","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Research Site","city":"Yokohama","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Research Site","city":"Aguascalientes","zip":"20230","country":"Mexico","geoPoint":{"lat":21.88262,"lon":-102.2843}},{"facility":"Research Site","city":"Guadalajara","zip":"44280","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"Research Site","city":"Mexico City","zip":"0 3100","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Research Site","city":"Mérida","zip":"97134","country":"Mexico","geoPoint":{"lat":20.967,"lon":-89.62318}},{"facility":"Research Site","city":"México","zip":"04700","country":"Mexico","geoPoint":{"lat":31.00435,"lon":-108.15213}},{"facility":"Research Site","city":"Orizaba","zip":"94300","country":"Mexico","geoPoint":{"lat":18.85195,"lon":-97.09957}},{"facility":"Research Site","city":"La Libertad","zip":"13013","country":"Peru","geoPoint":{"lat":-11.84178,"lon":-75.30261}},{"facility":"Research Site","city":"Lima","zip":"15033","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"L27","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"LIMA 27","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"LIMA 34","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Lima","zip":"LIMA 41","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Research Site","city":"Cebu City","zip":"6000","country":"Philippines","geoPoint":{"lat":10.31672,"lon":123.89071}},{"facility":"Research Site","city":"City of Taguig","zip":"1634","country":"Philippines","geoPoint":{"lat":14.5243,"lon":121.0792}},{"facility":"Research Site","city":"Iloilo City","zip":"5000","country":"Philippines","geoPoint":{"lat":10.69694,"lon":122.56444}},{"facility":"Research Site","city":"Makati","zip":"1229","country":"Philippines","geoPoint":{"lat":16.412,"lon":121.1226}},{"facility":"Research Site","city":"Manila","zip":"1015","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"facility":"Research Site","city":"Quezon City","country":"Philippines","geoPoint":{"lat":14.6488,"lon":121.0509}},{"facility":"Research Site","city":"Bydgoszcz","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Research Site","city":"Elblag","zip":"02-300","country":"Poland","geoPoint":{"lat":54.1522,"lon":19.40884}},{"facility":"Research Site","city":"Gdansk","zip":"80-952","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Research Site","city":"Olsztyn","zip":"10-228","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Research Site","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Research Site","city":"Chelyabinsk","zip":"454087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Research Site","city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"115533","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Moscow","zip":"125367","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"Research Site","city":"Rostov-on-Don","zip":"344037","country":"Russia","geoPoint":{"lat":47.21997,"lon":39.70769}},{"facility":"Research Site","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Busan","zip":"48108","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Research Site","city":"Chungcheongbuk-do","zip":"28644","country":"South Korea"},{"facility":"Research Site","city":"Gyeongsangnam-do","zip":"52727","country":"South Korea"},{"facility":"Research Site","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"6351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Research Site","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Research Site","city":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Research Site","city":"Khon Kaen","zip":"40002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}},{"facility":"Research Site","city":"Mueang","zip":"50200","country":"Thailand"},{"facility":"Research Site","city":"Ankara","zip":"06230","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Ankara","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Antalya","zip":"07059","country":"Turkey (Türkiye)","geoPoint":{"lat":36.90812,"lon":30.69556}},{"facility":"Research Site","city":"Diyarbakır","zip":"21280","country":"Turkey (Türkiye)","geoPoint":{"lat":37.91363,"lon":40.21721}},{"facility":"Research Site","city":"Istanbul","zip":"34030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Research Site","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Research Site","city":"Hanoi","zip":"100000","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"Research Site","city":"Hanoi","zip":"10000","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}},{"facility":"Research Site","city":"Ho Chi Minh City","zip":"700000","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}}]},"referencesModule":{"seeAlsoLinks":[{"label":"SAP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D933KC00001&amp;attachmentIdentifier=c84b8a9a-ab3b-42d9-beef-8e42857afd0d&amp;fileName=D933KC00001_-___Statistical_Analysis_Plan_-_Redacted.pdf&amp;versionIdentifier="},{"label":"CSP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D933KC00001&amp;attachmentIdentifier=734b41e6-780c-402f-a50f-4a03f71afabb&amp;fileName=D933KC00001_-_Protocol_-_Redacted.pdf&amp;versionIdentifier="},{"label":"CSR Synopsis","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D933KC00001&amp;attachmentIdentifier=ed59b3e6-e0a6-4b8b-96e1-49b8ff510ee7&amp;fileName=D933KC00001_-_Study_Synopsis_-_Redacted.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The study had a screening period (up to 28 days), followed by a treatment and follow-up period (up to 1960 days). A total of 328 participants were randomized in a 2:1 ratio to receive durvalumab + standard of care (SoC) concurrent chemoradiotherapy (cCRT) group or placebo + SoC cCRT group.","recruitmentDetails":"This Phase III double-blind, placebo-controlled study was conducted in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) at 87 study centers in North and South America, Europe, and Asia Pacific. The results are reported for analysis with assessment until data cut-off (DCO) date of 07 September 2023.","groups":[{"id":"FG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 milligram (mg) intravenous (IV) infusion every 4 weeks (Q4W) until progressive disease (PD) or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/square meter (m\\^2) on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin area under the plasma drug concentration-time curve (AUC) 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 every 3 weeks (Q3W) given either as 1 induction cycle prior to initiation of radiation therapy (RT) or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT) was delivered using external beam radiation therapy (EBRT) of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"FG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"219"},{"groupId":"FG001","numSubjects":"109"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"218"},{"groupId":"FG001","numSubjects":"109"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"219"},{"groupId":"FG001","numSubjects":"109"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"142"},{"groupId":"FG001","numSubjects":"69"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Ongoing treatment and in follow-up at data cut off","reasons":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"37"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Full analysis set (FAS) included all randomized participants.","groups":[{"id":"BG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"BG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"219"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"328"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.8","spread":"8.96"},{"groupId":"BG001","value":"62.4","spread":"9.50"},{"groupId":"BG002","value":"62.6","spread":"9.13"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"82"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"246"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"203"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"104"}]},{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"14"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"54"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"186"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"274"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions. Median PFS was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"9.5","upperLimit":"16.9"},{"groupId":"OG001","value":"9.4","lowerLimit":"7.5","upperLimit":"16.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The hazard ratio (HR) and confidence intervals (CIs) were calculated using a stratified Cox proportional hazards model, adjusting for age \\[\\< 65 versus (vs.) \\>= 65 years\\] and stage (IIIA vs. IIIB/C), with treatment as the only covariate and ties handled by Efron approach.","nonInferiorityType":"SUPERIORITY","pValue":"0.247","statisticalMethod":"Log Rank","statisticalComment":"The analysis was performed using the stratified log-rank test, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C).","paramType":"Hazard Ratio (HR)","paramValue":"0.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.647","ciUpperLimit":"1.123"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"The ORR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of complete response (CR) or partial response (PR) based on all participants in the FAS. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","lowerLimit":"53.9","upperLimit":"67.2"},{"groupId":"OG001","value":"60.6","lowerLimit":"50.7","upperLimit":"69.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.976","statisticalMethod":"Cochran-Mantel-Haenszel","statisticalComment":"The analysis was performed using a Cochran-Mantel-Haenszel (CMH) test, stratified by age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C).","paramType":"Difference in percentages","paramValue":"0.2","ciPctValue":"99.50","ciNumSides":"TWO_SIDED","ciLowerLimit":"-15.2","ciUpperLimit":"16.3","estimateComment":"The CIs for difference in percentages were estimated using Miettinen and Nurminen's method."}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"The OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. Median OS was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From screening until confirmed PD, assessed up to the DCO date (a maximum of approximately 1988 days).","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"26.2","upperLimit":"45.6"},{"groupId":"OG001","value":"29.5","lowerLimit":"23.2","upperLimit":"45.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C), with treatment as the only covariate and ties handled by Efron approach.","pValue":"0.823","statisticalMethod":"Log Rank","statisticalComment":"The analysis was performed using the stratified log-rank test, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C).","paramType":"Hazard Ratio (HR)","paramValue":"1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.778","ciUpperLimit":"1.386"}]},{"type":"SECONDARY","title":"Percentage of Participants Alive at 24 Months From Randomization (OS24)","description":"The OS24 was defined as the Kaplan-Meier estimate of OS at 24 months. Median OS24 was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 24","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","lowerLimit":"51.6","upperLimit":"64.7"},{"groupId":"OG001","value":"59.5","lowerLimit":"49.6","upperLimit":"68.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"For the comparison between treatments, the Kaplan-Meier estimator of survival at 24 months for each treatment was used to obtain the HR and the test is based on the method described in Klein 2007. To account for the stratification factors, the estimates and test statistics in each strata were combined by weighting inversely proportionately according to each within stratum variance.","pValue":"0.847","statisticalMethod":"Log Rank","statisticalComment":"The analysis was performed using the stratified log-rank test, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C).","paramType":"Hazard Ratio (HR)","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.716","ciUpperLimit":"1.502"}]},{"type":"SECONDARY","title":"Complete Response Rate (CRR)","description":"The CRR per RECIST 1.1 using BICR was defined as the percentage of participants with a confirmed response of CR. The CR was defined as disappearance of all target lesions since baseline.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.5","upperLimit":"4.6"},{"groupId":"OG001","value":"1.8","lowerLimit":"0.2","upperLimit":"6.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The analysis was performed using a CMH test, stratified by age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C).","paramType":"Difference in percentages","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.8","ciUpperLimit":"3.0","estimateComment":"The CIs for difference in percentages was calculated using Miettinen and Nurminen's method."}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"The DoR per RECIST 1.1 using BICR was defined as the time from the date of first documented response (which was subsequently confirmed) until the first date of documented progression or death in the absence of PD. The CR was defined as disappearance of all target lesions since baseline. The PR was defined as at least a 30% decrease in the sum of the diameters of target lesions. The DoR was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants. Only participants with objective response are analyzed.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"months","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","lowerLimit":"8.8","upperLimit":"NA","comment":"Upper limit of inter-quartile range could not be calculated as it was not reached as there were an insufficient number of participants with events."},{"groupId":"OG001","value":"18.6","lowerLimit":"7.4","upperLimit":"56.5"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"The DCR at 24 weeks per RECIST 1.1 using BICR was defined as the percentage of participants who had a best objective response of CR or PR in the first 25 weeks (to allow for late assessment within the assessment window) or who had stable disease for \\>= 23 weeks after randomization (to allow for an early assessment within the ± 1 week assessment window).","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 24","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8"},{"groupId":"OG001","value":"65.1"}]}]}]},{"type":"SECONDARY","title":"Time to Death or Distant Metastasis (TTDM)","description":"The TTDM per RECIST 1.1 using BICR was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that was outside the radiation field according to RECIST 1.1 or proven by biopsy.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","lowerLimit":"25.0","upperLimit":"NA","comment":"Upper limit of inter-quartile range could not be calculated as it was not reached as there were an insufficient number of participants with events."},{"groupId":"OG001","value":"46.3","lowerLimit":"16.6","upperLimit":"NA","comment":"Upper limit of inter-quartile range could not be calculated as it was not reached as there were an insufficient number of participants with events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C), with treatment as the only covariate and ties handled by Efron approach.","pValue":"0.790","statisticalMethod":"Log Rank","statisticalComment":"The analysis was performed using the stratified log-rank test, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C).","paramType":"Hazard Ratio (HR)","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.649","ciUpperLimit":"1.413"}]},{"type":"SECONDARY","title":"Time From Randomization to Second Progression (PFS2)","description":"The PFS2 was defined as the time from the date of randomization to the earliest of the progression event (subsequent to that used for the primary variable PFS per Investigator assessment) or death. The date of the second progression was recorded by the Investigator and defined according to local standard clinical practice and could have involved any of objective radiological, symptomatic progression, or death. Median PFS2 was calculated using the Kaplan-Meier technique.","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"109"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","lowerLimit":"21.8","upperLimit":"35.8"},{"groupId":"OG001","value":"22.0","lowerLimit":"16.2","upperLimit":"28.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C), with treatment as the only covariate and ties handled by Efron approach.","pValue":"0.132","statisticalMethod":"Log Rank","statisticalComment":"The analysis was performed using the stratified log-rank test, adjusting for age (\\< 65 vs. \\>= 65 years) and stage (IIIA vs. IIIB/C).","paramType":"Hazard Ratio (HR)","paramValue":"0.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.614","ciUpperLimit":"1.071"}]},{"type":"SECONDARY","title":"Serum Concentration of Durvalumab","description":"Blood samples were collected to determine the concentration of durvalumab.","populationDescription":"The Pharmacokinetic (PK) analysis set included all participants who received at least 1 dose of durvalumab or matching placebo per protocol, for whom any post-dose data were available and did not violate or deviate from the protocol in ways that would significantly affect the PK analyses. Only participants analyzed at specific timepoint are reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram per milliliter","timeFrame":"End of infusion on Week 0, pre-infusion on Weeks 4 and 12, and Month 3 follow-up","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"190"}]}],"classes":[{"title":"Week 0: End of infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"452.21","spread":"78.94"}]}]},{"title":"Week 4: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.02","spread":"80.85"}]}]},{"title":"Week 12: Pre-infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"123.39","spread":"163.20"}]}]},{"title":"Month 3 Follow-up","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.79","spread":"243.41"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab","description":"Blood samples were collected to determine the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence was defined as the number of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as either treatment-induced (post-baseline ADA positive only) or treatment-boosted ADA (baseline positive ADA titer that was boosted to \\>= 4-fold during the study period). Treatment-induced ADA was defined as ADA positive only post-baseline and not detected at baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive assessments with at least 16 weeks between the first and last positive assessment, or ADA positive at the last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment without fulfilling the conditions for persistently positive.","populationDescription":"The ADA analysis set included all participants who had non-missing baseline ADA and at least 1 non-missing post-baseline ADA result.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Pre-dose on Day 1 of Cycles 1, 2 and 4","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"}]}],"classes":[{"title":"ADA positive at any visit (ADA prevalence)","categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]},{"title":"Treatment-emergent ADA positive (ADA incidence)","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"ADA positive at both baseline and post-baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Treatment-induced ADA","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"ADA positive at baseline only","categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Persistent positive","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Transient positive","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"nAb positive at any visit","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Average Over 12 Months","description":"Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a total score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status scale with higher scores on the global health status/quality of life (QoL) and functioning scales representing better health status/function, but higher scores on symptom scales/items representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as a change from baseline of \\>=10.","populationDescription":"The FAS included all randomized participants. Only participants analyzed at baseline through Month 12 are reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"At screening, 2, 4, 6, 8, 12, 16, and 20 weeks after randomization, then every 8 weeks ±1 week up to 52 weeks, and then every 12 weeks ±1 week thereafter until PFS2. Assessed up to 12 months.","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"95"}]}],"classes":[{"title":"EORTC QLQ-C30: Global health status/QoL","categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","lowerLimit":"-2.3","upperLimit":"1.4"},{"groupId":"OG001","value":"0.2","lowerLimit":"-2.4","upperLimit":"2.8"}]}]},{"title":"EORTC QLQ-C30: Physical functioning","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","lowerLimit":"-3.0","upperLimit":"0.2"},{"groupId":"OG001","value":"-0.8","lowerLimit":"-3.1","upperLimit":"1.4"}]}]},{"title":"EORTC QLQ-C30: Fatigue symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"-0.9","upperLimit":"3.4"},{"groupId":"OG001","value":"0.3","lowerLimit":"-2.8","upperLimit":"3.3"}]}]},{"title":"EORTC QLQ-C30: Appetite loss symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"0.9","upperLimit":"5.2"},{"groupId":"OG001","value":"0.3","lowerLimit":"-2.7","upperLimit":"3.3"}]}]},{"title":"EORTC QLQ-LC13: Dyspnoea symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"-1.0","upperLimit":"3.1"},{"groupId":"OG001","value":"-1.3","lowerLimit":"-4.2","upperLimit":"1.6"}]}]},{"title":"EORTC QLQ-LC13: Cough symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","lowerLimit":"-8.6","upperLimit":"-3.6"},{"groupId":"OG001","value":"-6.5","lowerLimit":"-10.0","upperLimit":"-2.9"}]}]},{"title":"EORTC QLQ-LC13: Pain in chest symptoms","categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","lowerLimit":"-4.2","upperLimit":"0.4"},{"groupId":"OG001","value":"-0.8","lowerLimit":"-3.9","upperLimit":"2.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE is the development of any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A SAE is an AE occurring during any study phase, that fulfils 1 or more of the following criteria: death, life-threatening, in-participant hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital abnormality or birth defect, and an important medical event that may jeopardize the participant or may require medical treatment to prevent 1 of the outcomes listed above. AEs leading to discontinuation of study treatment were those with action taken was 'Drug Permanently Discontinued' for any study treatment.","populationDescription":"The Safety analysis set included all participants who received at least 1 dose of randomized treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From time of signature of informed consent up to 90 days after last dose of study treatment or up to the date of initiation of the first subsequent therapy, whichever occurs first, approximately 1988 days.","groups":[{"id":"OG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."},{"id":"OG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"108"}]}],"classes":[{"title":"Any AE","categories":[{"measurements":[{"groupId":"OG000","value":"98.6"},{"groupId":"OG001","value":"100.0"}]}]},{"title":"Any SAE","categories":[{"measurements":[{"groupId":"OG000","value":"47.0"},{"groupId":"OG001","value":"51.9"}]}]},{"title":"Any AE leading to discontinuation of treatment","categories":[{"measurements":[{"groupId":"OG000","value":"34.7"},{"groupId":"OG001","value":"19.4"}]}]},{"title":"Any immune-mediated AE","categories":[{"measurements":[{"groupId":"OG000","value":"48.9"},{"groupId":"OG001","value":"28.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From time of signature of informed consent up to 90 days after last dose of study treatment or up to the date of initiation of the first subsequent therapy, whichever occurs first, approximately 1988 days.","description":"The Safety analysis set included all participants who received at least 1 dose of randomized treatment. All-cause mortality was determined for participants in FAS.","eventGroups":[{"id":"EG000","title":"Durvalumab + SoC CRT","description":"Participants received durvalumab 1500 mg IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days).","deathsNumAffected":142,"deathsNumAtRisk":219,"seriousNumAffected":103,"seriousNumAtRisk":219,"otherNumAffected":209,"otherNumAtRisk":219},{"id":"EG001","title":"Placebo + SoC CRT","description":"Participants received placebo matching with durvalumab IV infusion Q4W until PD or specific treatment discontinuation criteria were met.\n\nParticipants received SOC CRT, consisting of concurrent radiotherapy and IV infusion of 1 of the following chemotherapy regimens.\n\n1. Cisplatin + Etoposide: Cisplatin 50 mg/m\\^2 on Days 1 and 8 and etoposide 50 mg/m\\^2 on Days 1 to 5 Q4W of each 28-day cycle for 2 cycles plus 1 additional optional induction cycle.\n2. Carboplatin + Paclitaxel: Carboplatin AUC 2 and paclitaxel 40-50 mg/m\\^2 on Day 1 weekly basis for 6 weeks. Optional: Carboplatin AUC 5-6 and paclitaxel 175-200 mg/m\\^2 Q3W given either as 1 induction cycle prior to initiation of RT or as 1-2 consolidation cycles after completion of RT.\n3. Cisplatin + Pemetrexed: Cisplatin 75 mg/m\\^2 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 3 cycles plus 1 additional optional induction cycle.\n4. Carboplatin + Pemetrexed: Carboplatin AUC 5 and pemetrexed 500 mg/m\\^2 on Day 1 of each 21-day cycle for 4 cycles.\n\nRadiation: Either standard 3DCRT or IMRT was delivered using EBRT of 5 fractions per week for \\~6 weeks (± 3 days).","deathsNumAffected":69,"deathsNumAtRisk":109,"seriousNumAffected":56,"seriousNumAtRisk":108,"otherNumAffected":106,"otherNumAtRisk":108}],"seriousEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Oesophageal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Mesenteric lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Condition aggravated","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":108}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Acute hepatitis C","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Brain abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Mastoiditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":29,"numAtRisk":219},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":108}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":108}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":108}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Septic coagulopathy","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":108}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":108}]},{"term":"Extradural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":219},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":108}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":219},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":108}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":219},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":108}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Myelodysplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Oesophageal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Amyotrophic lateral sclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Basal ganglia haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Carotid artery thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":108}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":108}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":108}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Organising pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":219},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":108}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":219},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":108}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":219},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":108}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":219},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":108}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Toxic epidermal necrolysis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Hypereosinophilic syndrome","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":219},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":108}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":219},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":108}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":71,"numAffected":55,"numAtRisk":219},{"groupId":"EG001","numEvents":30,"numAffected":26,"numAtRisk":108}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":219},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":108}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":219},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":108}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":29,"numAtRisk":219},{"groupId":"EG001","numEvents":27,"numAffected":18,"numAtRisk":108}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":28,"numAtRisk":219},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":108}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":30,"numAtRisk":219},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":108}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":36,"numAtRisk":219},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":108}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":29,"numAtRisk":219},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":108}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":96,"numAffected":59,"numAtRisk":219},{"groupId":"EG001","numEvents":33,"numAffected":28,"numAtRisk":108}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":219},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":108}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":219},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":108}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":44,"numAtRisk":219},{"groupId":"EG001","numEvents":21,"numAffected":19,"numAtRisk":108}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":219},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":108}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":21,"numAtRisk":219},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":108}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":13,"numAtRisk":219},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":108}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":16,"numAtRisk":219},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":108}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":38,"numAtRisk":219},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":108}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":33,"numAtRisk":219},{"groupId":"EG001","numEvents":18,"numAffected":17,"numAtRisk":108}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":26,"numAtRisk":219},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":108}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":219},{"groupId":"EG001","numEvents":16,"numAffected":11,"numAtRisk":108}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":219},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":108}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":10,"numAtRisk":219},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":108}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":24,"numAtRisk":219},{"groupId":"EG001","numEvents":12,"numAffected":8,"numAtRisk":108}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":17,"numAtRisk":219},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":108}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":105,"numAffected":90,"numAtRisk":219},{"groupId":"EG001","numEvents":52,"numAffected":40,"numAtRisk":108}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":24,"numAtRisk":219},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":108}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":219},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":108}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":46,"numAtRisk":219},{"groupId":"EG001","numEvents":24,"numAffected":21,"numAtRisk":108}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":25,"numAtRisk":219},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":108}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":20,"numAtRisk":219},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":108}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":219},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":108}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":219},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":108}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":219},{"groupId":"EG001","numEvents":11,"numAffected":5,"numAtRisk":108}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":219},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":108}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":26,"numAtRisk":219},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":108}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":46,"numAtRisk":219},{"groupId":"EG001","numEvents":23,"numAffected":18,"numAtRisk":108}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":20,"numAtRisk":219},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":108}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":219},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":108}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":219},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":108}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":219},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":108}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":219},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":108}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":219},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":108}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":27,"numAtRisk":219},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":108}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":36,"numAtRisk":219},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":108}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":22,"numAtRisk":219},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":108}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":219},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":108}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":219},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":108}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":219},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":108}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":35,"numAtRisk":219},{"groupId":"EG001","numEvents":34,"numAffected":31,"numAtRisk":108}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":30,"numAtRisk":219},{"groupId":"EG001","numEvents":18,"numAffected":10,"numAtRisk":108}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":219},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":108}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":29,"numAtRisk":219},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":108}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":48,"numAtRisk":219},{"groupId":"EG001","numEvents":28,"numAffected":19,"numAtRisk":108}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca","email":"information.center@astrazeneca.com","phone":"1-877-240-9479"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-03-04","uploadDate":"2024-09-06T01:48","filename":"Prot_000.pdf","size":969574},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-04-27","uploadDate":"2024-12-16T13:14","filename":"SAP_002.pdf","size":5191199}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-10-02","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D002277","term":"Carcinoma"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"C075609","term":"PE regimen"},{"id":"C053518","term":"CP protocol"},{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"},{"id":"D011827","term":"Radiation"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D055585","term":"Physical Phenomena"}]}},"hasResults":true}